Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/14/2023 | Buy → Hold | Needham | |
| 3/16/2023 | $24.00 | Buy | Stifel |
| 12/14/2022 | $22.00 | Buy | Needham |
| 6/30/2022 | $22.00 | Buy | H.C. Wainwright |
| 11/1/2021 | $25.00 | Overweight | Cantor Fitzgerald |
| 11/1/2021 | $24.00 | Outperform | Wedbush |
| 11/1/2021 | $28.00 | Outperform | SVB Leerink |
| 11/1/2021 | $23.00 | Buy | Jefferies |
-- Theseus Stockholders to Receive $4.05 Per Share in Cash Plus Contingent Value Right -- CAMBRIDGE, Mass., Feb. 14, 2024 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) ("Theseus" or the "Company"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced that Concentra Biosciences, LLC ("Concentra") through its wholly owned subsidiary, Concentra Merger Sub II, Inc. ("Merger Sub"), has successfully completed the previously announced tender offer to acquire all outstanding shares of Theseus common stock for a price per share of (i) $4
As previously announced on December 22, 2023, Concentra Biosciences, LLC ("Parent") and its wholly owned subsidiary, Concentra Merger Sub II, Inc. ("Purchaser"), entered into a merger agreement (the "Merger Agreement") with Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) ("Theseus") whereby Purchaser will acquire Theseus for a price per share of Theseus common stock ("Theseus common stock") between $3.90 and $4.05 in cash, consisting of (i) a base cash price of $3.90 per share (the "Base Price") and (ii) an additional cash amount of up to $0.15 per share (the "Additional Price Per Share" and together with the Base Price, the "Cash Amount"), plus one non-tradeable contingent value right ("CVR")
CAMBRIDGE, Mass., Dec. 22, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) ("Theseus" or the "Company"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced it has entered into a definitive merger agreement (the "Merger Agreement") whereby Concentra Biosciences, LLC ("Concentra") will acquire Theseus for a price per share of Theseus common stock ("Theseus common stock") of between $3.90 and $4.05 in cash, consisting of (i) a base cash price of $3.90 per share (the "Base Price") and (ii) an additional cash amount of not more
SC 13D/A - Theseus Pharmaceuticals, Inc. (0001745020) (Subject)
SC 13G/A - Theseus Pharmaceuticals, Inc. (0001745020) (Subject)
SC 13D/A - Theseus Pharmaceuticals, Inc. (0001745020) (Subject)
4 - Theseus Pharmaceuticals, Inc. (0001745020) (Issuer)
4 - Theseus Pharmaceuticals, Inc. (0001745020) (Issuer)
4 - Theseus Pharmaceuticals, Inc. (0001745020) (Issuer)
15-12G - Theseus Pharmaceuticals, Inc. (0001745020) (Filer)
EFFECT - Theseus Pharmaceuticals, Inc. (0001745020) (Filer)
S-8 POS - Theseus Pharmaceuticals, Inc. (0001745020) (Filer)
As previously announced on December 22, 2023, Concentra Biosciences, LLC ("Parent") and its wholly owned subsidiary, Concentra Merger Sub II, Inc. ("Purchaser"), entered into a merger agreement (the "Merger Agreement") with Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) ("Theseus") whereby Purchaser will acquire Theseus for a price per share of Theseus common stock ("Theseus common stock") between $3.90 and $4.05 in cash, consisting of (i) a base cash price of $3.90 per share (the "Base Price") and (ii) an additional cash amount of up to $0.15 per share (the "Additional Price Per Share" and together with the Base Price, the "Cash Amount"), plus one non-tradeable contingent value right ("CVR") r
Theseus Pharmaceuticals Inc (NASDAQ:THRX) on Friday, has entered into a definitive merger agreement whereby Concentra Biosciences LLC will acquire Theseus for a price per share of between $3.90 and $4.05 in cash, consisting of a base cash price of $3.90 per share and an additional cash amount of not more than $0.15 per share at the closing of the merger, plus one non-tradeable contingent value right (CVR). CVR represents the right to receive 80% of the net proceeds from any license or disposition of Theseus' programs effected within 180 days of closing of the merger and 50% of the potential aggregate value of certain specified potential cost savings realized within 180 days of the close of
Needham downgraded Theseus Pharmaceuticals from Buy to Hold
Stifel initiated coverage of Theseus Pharmaceuticals with a rating of Buy and set a new price target of $24.00
Needham initiated coverage of Theseus Pharmaceuticals with a rating of Buy and set a new price target of $22.00
All sites open and actively enrolling in Phase 1 portion of Phase 1/2 clinical trial of THE-630 in advanced GIST; preliminary dose escalation data expected in Q2 2023 Preclinical data characterizing THE-349 in EGFR-mutant NSCLC presented at 2022 EORTC-NCI-AACR Symposium; IND application submission expected in H2 2023 $221.0 million in cash, cash equivalents, and investments as of September 30, 2022; expected to fund operations into the fourth quarter of 2024 CAMBRIDGE, Mass., Nov. 3, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, deve
CAMBRIDGE, Mass., Oct. 19, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced the appointment of Steven Stein, M.D. to its Board of Directors. "We are delighted to welcome Dr. Stein to the Theseus Board as we advance development of our THE-630 and THE-349 programs, while also expanding our early-stage pipeline," said Tim Clackson, Ph.D., President and Chief Executive Officer of Theseus. "Dr. Stein's depth and breadth of oncology expertise, and extens
THE-630 Phase 1/2 clinical trial enrolling patients; initial data expected in Q2 2023 Nomination of development candidate for fourth-generation epidermal growth factor receptor (EGFR) inhibitor program expected in Q3 2022; IND expected in 2023 $228.6 million in cash, cash equivalents, and investments as of June 30, 2022; expected to fund operations into the fourth quarter of 2024 CAMBRIDGE, Mass., Aug. 11, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today anno